Please join us in welcoming the following new corporate partners contributing their support to the HBA mission.
CEO: Joseph C. Papa
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health.
Daiichi Sankyo, Inc.
President and CEO: Ken Keller
Daiichi Sankyo, Inc. is the U.S. subsidiary of Daiichi Sankyo, Co., Ltd. Daiichi Sankyo, Inc. medicines approved in the U.S. include therapies for hypertension, dyslipidemia, diabetes, thrombosis, stroke risk reduction, acute coronary syndrome, IV iron therapy, metastatic melanoma, tenosynovial giant cell tumors and metastatic breast cancer.
CEO: Tom Joyce
Danaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving the quality of life around the world. Its family of world-class brands has leadership positions in the demanding and attractive health care, environmental and applied end-markets. Danaher's globally diverse team of more than 60,000 associates is united by a common culture and operating system, the Danaher Business System and its shared purpose, helping realize life's potential. (NASDAQ: DHR, revenue ~$20B).
CEO: Graeme Duncan
A global pharmaceutical company focused on serving the needs of patients and healthcare providers around the world with enhanced access to niche established medicines. We invest in revitalising and innovating niche established medicines that, without our focus, may otherwise not be available. We do this because we want patients to live healthier, better lives, by providing healthcare professionals with medicines that help optimise treatment.
CEO: Jacquie Cleary
Atlas is a global company that provides solutions that drive results to new levels. We are a leading provider of program management and delivery solutions in the U.S. and European markets. Our suite of services includes management consulting, managed services, development and workforce solutions. Clients look to Atlas to design strategic teams with tangible outcomes.
CEO: Stan Woodland
CMI/Compas is the leading media resource and indispensable partner for the world’s top healthcare companies. Our methodology of precision, performance and people enables us to take a channel-agnostic approach to identifying, engaging and influencing target audiences. With offices across the U.S., we are actively recruiting people who are looking for a rewarding career in healthcare marketing.
Faegre Drinker Biddle & Reath LLP
Deputy practice group leader: Jennifer Breuer
Faegre Drinker is a firm designed for clients, providing exceptional transactional, litigation and regulatory services to organizations ranging from emerging enterprises to multinational companies. Our more than 1,300 attorneys, consultants and professionals in 14 practices and 22 locations across the United States, in the United Kingdom and in China, all have one shared focus: you, the client.
CEO: Bill Bunker
Navigating Cancer is the leading patient relationship management technology and solutions company focused on improving the patient experience, delivering more effective care management and enabling oncology care innovation. With over 1,700 providers adopting the Navigating Care™ platform, it is the most broadly deployed patient management solution in oncology.
CEO: Ram Sharma
Analytical Wizards is an advanced analytics company that is revolutionizing healthcare analytics by combining its scalable platforms, AI/ML solutions and deep domain expertise to drive actionable insights.
CEO: Rob Armstrong
Boston Pharmaceuticals is a translational drug development company founded in 2016 by Chris Viehbacher, ex-CEO of Sanofi and Rob Armstrong, ex-R&D executive from Eli Lilly. Our business model focuses on partnering and developing therapeutics from late preclinical to clinical POC. We have built an experienced clinical development team and acquired a diverse portfolio of fifteen programs in oncology, autoimmune, cardiovascular, dermatology, anti-infective, gastrointestinal and metabolic.
CEO: Tassos Gianakakos
Change the world for people with serious cardiovascular diseases through bold and innovative science, we’re pioneering a precision medicine approach to treating cardiomyopathies and other forms of heart failure that results from biomechanical defects in cardiac muscle contraction.
RWS Life Sciences
CEO: Richard Thompson, managing director of life sciences division: Jon Hart
RWS Life Sciences has a 30-year history of providing a full suite of language services exclusively for the life sciences industry. We provide language solutions for clinical trial management and linguistic validation of clinical outcomes assessments (COAs) – with extensive experience in a variety of therapeutic areas, regulatory affairs, medical device documentation, marketing and communications and e-learning and training programmes.